NCT06079775View on ClinicalTrials.gov

P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants

PHASE1RecruitingINTERVENTIONAL

Enrollment

71

Participants

Timeline

Start Date

January 30, 2024

Primary Completion Date

August 12, 2025

Study Completion Date

October 7, 2025

Conditions

Bacterial Infections

Interventions

DRUG

Xeruborbactam Oral Prodrug

Experimental

DRUG

Ceftibuten

Experimental

DRUG

Xeruborbactam Oral Prodrug Placebo

Placebo Comparator

DRUG

Ceftibuten Placebo

Placebo Comparator

Trial Locations (1)

5000

RECRUITING

CMAX, Adelaide

All Listed Sponsors

collaborator

Shionogi Inc.

INDUSTRY

collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Qpex Biopharma, Inc.

INDUSTRY